Hughes Owen 4

What Happened
Hughes Owen, a director of ANAPTYSBIO, was awarded 11,250 restricted stock units (RSUs) on May 11, 2026. The RSUs were granted at no cash cost (reporting price $0.00) and are reported as a derivative award—each RSU is a contingent right to one share of common stock upon settlement.

Key Details

• Transaction date (period of report): May 11, 2026; Form 4 filed May 13, 2026.
• Transaction type/code: Award/Grant (derivative RSUs) — 11,250 RSUs at $0.00.
• Total reported value at grant: $0 (no cash paid; value will depend on future stock price at settlement).
• Vesting (footnotes): 1/3 of the RSUs vest on May 11, 2027, then 1/3 vest in equal annual installments thereafter until fully vested, subject to continued service. (Each RSU converts to one share upon settlement for no consideration.)
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form was filed two days after the period date (May 11 report, May 13 filing); no late-filing flag indicated.

Context
RSU grants to directors are common compensation and are time-based awards that convert into shares only after vesting/settlement. This grant does not represent an open-market purchase or sale and does not immediately change the public float; its monetary value to the insider will depend on ANAB’s share price when the RSUs vest and are settled.